# Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2

> **NCT02907021** · PHASE1 · COMPLETED · sponsor: **Population Health Research Institute** · enrollment: 20 (actual)

## Conditions studied

- Heart Failure
- Breast Cancer

## Interventions

- **DRUG:** standard-of-care treatments for LV impairment

## Key facts

- **NCT ID:** NCT02907021
- **Lead sponsor:** Population Health Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-01
- **Primary completion:** 2018-04-12
- **Final completion:** 2018-04-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02907021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02907021, "Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02907021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*